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are 1.61 times less likely to relapse; those with sponsors are 1.64 times less likely to
relapse), cetertis paribus. Adjustor covariates include: Global Assessment of Func-
tioning, addiction severity, DSM diagnosis and length of stay. CONCLUSIONS:
Since this survival model relates the time that passes before relapse occurs to
known risk factors for relapse, this research will help treatment providers identify
not only the best types of interventions but also the correct timing of interventions.
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OBJECTIVES: In previous studies, psychopathology particularly negative, depres-
sive and cognitive syndromes adversely influenced health-related quality of life
(HRQoL). The objective of the study was to examine the relationship between
schizophrenia symptoms and the HRQoL dimensions of the EQ-5D descriptive
system. METHODS: This was a cross-sectional study conducted at the Psychiatric
Clinic, Universiti Kebangsaan Malaysia Medical Centre. Patients were assessed for
symptom severity using the Clinical Global Impressions-Schizophrenia (CGI-SCH)
severity scale (scores range from (1) no illness to (7) most severe possible) by the
attending clinicians. Patients’ perceived health states in 5 dimensions (mobility,
self-care, usual activities, pain/discomfort and anxiety/depression) with 3 levels of
response; (1) no problems, 2 (moderate problems) and 3 (extreme problems) were
evaluated using the EQ-5D descriptive system. The association between the 2
scales were examined by Spearman rank correlations. RESULTS: A total of 222
out-patients (Mean age 37.7, SD 10.1; Mean duration of illness  11.42, SD8.0)
with a DSM-IV chart diagnosis of schizophrenia participated in the study. There
was a moderate positive correlation between the EQ-5D ‘usual activities’ dimen-
sion and each of the CGI-SCH overall, depressive and cognitive symptom dimen-
sion scores (rs  0.35, 0.37 and 0.31, respectively & for all p  0.01). A significant
moderate correlation was also found between the EQ-5D ‘anxiety/depression’ and
the CGI-SCH depressive symptom dimension scores (rs  0.35, p  0.01). Weak
correlations were found between the CGI-SCH symptoms and other EQ-5D dimen-
sions scores (rs ranges from 0.16 to 0.26, p 0.01). CONCLUSIONS: In chronic
schizophrenics living in the community, worsening of overall, depressive and cog-
nitive symptoms were moderately associated with deterioration in patients’ usual
life activities and worsening of depressed mood was moderately associated with
worsening of anxiety or depression states. Schizophrenia syndromes were only
weakly associated with patients’ mobility, self-care and sense of pain or discom-
fort.
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OBJECTIVES: To ascertain changes in Health related Quality of Life (HRQL) among
young heroin users after one year follow-up.METHODS:Heroin users (18-30y) were
recruited in outdoor settings in three Spanish cities (Barcelona, Madrid, Seville)
from 2001 to 2003 and followed up, on average, 1.4(SD:0.6) years later. Standardised
laptop interviews included socio-demographic data, drug use patterns, health re-
lated issues, the Severity of Dependence Scale (SDS) and the Nottingham Health
Profile (NHP). For bivariate analyses, non parametric Mann-Whitney U and
Kruskal-Wallis tests were used. Factors associated to NHP score changes over time
were analysed through a multiple linear regression taking into account socio-de-
mographic factors, consumption patterns and health related variables.RESULTS:A
total of 628 subjects (72.5% males), mean age 27.9 (SD:3.4) years were followed
(63.4%). Mean total NHP score improved, from 36.4 (SD:24.2) at baseline to 27.0
(SD:22.4) at follow-up. Variables associated with total NHP score worsening were
HIV infection during follow-up, having experienced an overdose during the last 12
months and psychiatric treatment ever; conversely, total NHP score improved
among those who got a job by the end of the study. Each additional substance with
a weekly regular use and higher SDS scores for both cocaine and heroin, measured
as a difference from baseline values, were also related to worsening total NHP
score. We observed an interaction between severity of heroin dependence (as mea-
sured with SDS) and methadone maintenance treatment. The NHP total score only
improved, with decreasing heroin SDS, among drug users in methadone mainte-
nance treatment.CONCLUSIONS:HRQL improved over 12 months for young heroin
users. The main variables independently related with HRQL were changes in her-
oin and cocaine SDS. Further holistic models taking into account social variables
are needed.
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OBJECTIVES: Developing practical strategies to incorporate quality of life (QoL)
data in clinical management is an unmet need, and using quality of life (QoL) as a
predictor of clinical event is a new trend in outcomes research. The objective of this
study was to investigate relapse rate as a function of QoL in schizophrenic patients.
METHODS: We used data from EuroSC, a multicenter 2-year cohort study con-
ducted in France, England and Germany. We first examined the association be-
tween occurrence of relapse and baseline QoL, as measured by SF36 mental com-
posite score (MCS) and physical composite score (PCS), by EQ-5D and QOLI
subjective score. Then bivariate analyses were performed to identify confounding
factors (CF). Finally CF and QoL were incorporated in several multivariate Cox
models. RESULTS: Our sample consisted in 922 patients with schizophrenia. QoL
was found to be lower for those who relapsed (418 patients with MCS 40.1, PCS
47.1, EQ-5D utility  0.70 and QOLI  4.65 vs. 504 patients with MCS  43.9
(p0.0001), PCS  49.2 (p0.001), EQ-5D utility  0.77 (p0.0001), and QOLI  4.8
(p0.01)). Bivariate analyses identified several outcomes: age, gender, severity of
disease, depression, antipsychotic medication, compliance, subjective side effects
and functioning. Multivariate Cox models confirmed that a higher level of QoL
predicts a significantly lower rate of relapse at 2 years (HR  0.94, p0.03 for MCS;
HR 0.89; p0.01 for PCS; HR0.97; p0.001 for EQ-5D utility; HR0.83; p0.004 for
QOLI). CONCLUSIONS: This study shows that QoL can be considered as a mediator
of relapse in schizophrenia, independently of clinical severity scales. These results
are consistent with new research trends. Our findings can contribute to develop
credible strategies on how to integrate QoL data in clinical practice.
PMH55
AN EXAMINATION OF ANTIDEPRESSANT-RELATED SEXUAL DYSFUNCTION
AND DEGREE OF ENJOYMENT AND SATISFACTION WITH DAILY ACTIVITIES,
AND CURRENT MEDICATION IN EMPLOYED PATIENTS
Schneider G1, Roy A2, Dabbous OH3
1United BioSource Corporation, Lexington, MA, USA, 2Takeda Pharmaceuticals International, Inc,
Deerfield, IL, USA, 3Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA
OBJECTIVES: To understand the association of antidepressant-related sexual dys-
function with degree of enjoyment and satisfaction from daily activities, and cur-
rent medication. METHODS: Employed individuals (18 years of age) with depres-
sion (excluding bipolar disorder) completed a web-based computer-generated 25-
minute survey (population identified by Harris Interactive). Sexual dysfunction
(SD) was assessed using the Arizona Sexual Experience (ASEX) Scale on 5 compo-
nents of sexual functioning (Drive, Arousal, Penile Erection/Vaginal Lubrication,
Orgasm, Satisfaction); each rated on a 6-level ordinal scale (higher scores indicate
increased SD). Using distribution among current antidepressant users, overall SD
score was categorized into quartiles (lowest quartile represented better sexual
functioning). Degree of enjoyment and satisfaction related to general activity and
current medication was measured using a 5-point ordinal scale (1very poor and
5very good) using the Quality of Life Enjoyment and Satisfaction Questionnaire –
Short Form (QLESQ-SF). A summary “percent-of-max” score for general activity
items, transformed to 5-level ordinal variable employing cut-points of 20, 40, 60
and 80%, was used (20% represented the poorest experience). Gender stratified
cumulative logit models were used to estimate effect of SD on QLESQ measures.
RESULTS: Of 1,521 respondents, 872 (57%) reported current antidepressant use
(60.6% female, mean age 49.9 13.5 years). Among antidepressant users, compared
to the first SD quartile, odds of being in a poorer overall “percent-of-max” score (i.e.,
lower enjoyment/satisfaction) were greater in the highest (4th) SD quartile for both
males (odds ratio [OR] 3.03; p0.0007) and females (OR1.96; p0.0021). Sexual
dysfunction was associated with lack of satisfaction with medication for both gen-
ders: (males - 3rd SD quartile (OR2.17; p0.001); highest SD quartile (OR3.33;
p0.0003); females - highest SD quartile (OR1.49; p0.06)). CONCLUSIONS: These
data suggest that antidepressant-related SD may be associated with diminished
enjoyment and satisfaction with daily activities and current medication. Such per-
ceptions may impact eventual treatment outcomes.
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OBJECTIVES: There has been increased attention to the antipsychotic treatment of
negative symptoms in schizophrenia and the potential impact that this could have
on various functional outcomes. We compared the relative effects of negative
symptoms on functioning as compared to other symptoms. METHODS: Data are
from 18 months of the National Institute of Mental Health (NIMH) CATIE trial of
chronic schizophrenia (n1447). Measures were the Positive and Negative Syn-
drome Scale (PANSS), functioning from the Heinrich’s (Instrumental role, Common
place objects and activities) and items from the Lehman Quality of Life Scales
(Leisure activities, Instrumental activities of daily living). Quality of life items mea-
suring negative symptoms were excluded. Correlations between the five PANSS
factors and the functional measures were examined at baseline and change. Func-
tioning items were summed to create a standardized total score. Multiple regres-
sion was used to predict the functioning total score at baseline using the five PANSS
factors and change in functioning using change on the PANSS factors. RESULTS:
The negative symptom factor correlated more strongly than other symptom fac-
tors with functioning at baseline and change scores. Multiple regression predicting
functioning at baseline including all five PANSS factors showed that the negative
symptom factor was the strongest predictor, almost three times that of positive
symptoms (r-0.25 vs. r-0.07). A similar multiple regression predicting change in
total functioning with change on PANSS also found that the negative factor was the
best predictor and was double that of the positive factor (r-0.08 vs. r-0.045).
CONCLUSIONS: Baseline and change in functioning were more strongly related to
the PANSS negative factor than the other four PANSS factors. Since we focused on
negative symptoms we chose domains of functioning that did not overlap with
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negative symptoms. The results suggest that functioning and improvement in
functioning are more strongly correlated with negative than with positive and
other symptom factors.
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OBJECTIVES: To examine the association of antidepressant-related weight gain
with degree of enjoyment and satisfaction from general daily activities, medication
and overall quality of life.METHODS: Employed individuals (18 years of age) with
depression (excluding bipolar disorder) completed a web-based computer-gener-
ated 25-minute survey (population identified by Harris Interactive). Weight gain
was measured using the Toronto Side Effects Scale which measures medication-
related side effects in the two weeks preceding the survey, and analyzed as a
4-level ordinal variable (none, 2lbs, 4lbs, 7lbs). Degree of enjoyment and
satisfaction related to general activities, satisfaction with current medication, and
overall quality of life were measured using a 5-point ordinal scale (1very poor;
5very good) employing the Quality of Life Enjoyment and Satisfaction Question-
naire – Short Form (QLESQ-SF). A summary “percent-of-max” score was calculated
for general activity items, and transformed to a 5-level ordinal variable using cut-
points of 20, 40, 60 and 80% (20% represented least overall enjoyment/satisfac-
tion) . Gender stratified cumulative logit models were used to estimate the effect of
weight gain on QLESQ-SF measures.RESULTS:Of the 1,521 survey respondents, 872
(57%) reported current antidepressant use (60.6% female, mean age 49.9  13.5
years). Compared to females with no weight gain, the odds of having lower enjoy-
ment/satisfaction were greater for females who experienced any weight gain:
2lbs (odds ratio [OR]2.22; p0.0001),4lbs (OR2.27; p0.004) and7lbs
(OR12.50; p0.0001). Among males lower QLESQ score was associated only with
the 7lbs category (OR5.26; p0.0004). Satisfaction with medication was in-
versely associated with weight gain for females; 2lbs (OR1.49; p0.051),
4lbs (OR2.33; p0.002) and 7lbs (OR8.33; p0.0001) and males; 7lbs
(OR2.78; p0.031). CONCLUSIONS: These data suggest that antidepressant-re-
lated weight gain may have strong associations with patient perceptions of dimin-
ished enjoyment and satisfaction in general daily activities and with current med-
ication, which may affect medication adherence.
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OBJECTIVES: The goal of this research was to compare the effect of donepezil oral
standard tablets (OST) versus donepezil oral disintegrating tablets (ODT) on stress
and objective burden in caregivers of de novo patients with dementia of AD in
routine medical practice. METHODS: A 6-month, prospective, observational study
enrolled naïve patients with possible/probable AD according to DSM-IV/NINCDS-
ADRDA criteria. Comparison on caregiver stress and objective burden was carried-
out between donepezil formulations of OST and ODT for a 6 month period. The
self-administered ZARIT scale and daily hours devoted to the care of patients on
basic and instrumental activities of daily-living (BADL, IADL), behaviour supervi-
sion and nursing home institutionalization were computed. RESULTS: 547 naïve
and de novo AD patients were analyzed: 123 (22.5%) received OST and 424 (77.5%)
ODT, at 7.1 (2.5) and 7.1 (2.6) mg/day, respectively. No significant differences were
observed in age, sex distribution, schooling, educational training, or relationship
with main caregiver between groups. Baseline clinical characteristics (comorbidi-
ties, symptoms of dementia duration, MMSE scoring) were homogeneous between
groups and remained unchanged during the study; Adjusted ZARIT scoring was
reduced significantly in ODT group by -1.1 point (p0.001) but this was not statis-
tically higher than the reduction observed in OST cohort; -0.5 (p0.527 between
groups comparison). Daily hours of care on BADL and IADL were not statistically
different between cohorts and remained unchanged during the study. Also, aver-
age number of hours/day on behaviour supervision or general supervision and the
percentage of caregivers having to quit their jobs were similar. CONCLUSIONS:
Findings of this study show that both subjective and objective burden of caregivers
of de novo patients with AD treated with donepezil remain stables during the
6-month period of the study, and it is unrelated with type of formulation given to
patients.
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OBJECTIVES: Patients with major depressive disorder (MDD) frequently report
lower quality of life (QoL) and increased disability compared with the general pop-
ulation. This post hoc analysis describes the association between QoL, painful
physical symptoms (PPS), depressive symptoms and employment status in a Chi-
nese MDD patient cohort. METHODS: Chinese MDD patients (299) from a prospec-
tive observational study of six East Asian countries/regions were compared at base-
line and after 3 months of naturalistic treatment on QoL (EuroQoL Questionnaire-5
Dimensions [EQ-5D] utility score), PPS (Somatic Symptom Inventory [SSI]), depres-
sion (17-item Hamilton Depression Rating Scale [HAMD17]) and employment sta-
tus measures. Patients were classified as PPS positive or negative (PPS, PPS-; SSI
mean score 2 or 2 respectively). Effect sizes (ES) were calculated using Cohen’s
d. RESULTS: Patients who were employed at baseline reported higher QoL (EQ-5D:
0.60 vs. 0.42; ES 0.7) and were less severely ill (HAMD17 total score: 22.7 vs. 26.0; ES
-0.7) than those who were unemployed. Few transitions in employment status
were observed during the study. Self-reported QoL was low (EQ-5D: mean 0.52) at
baseline and improved substantially after 3 months (EQ-5D: 0.89). PPS patients
were more severely ill (HAMD17: 25.4 vs. 23.3; ES 0.4) and had a lower QoL (EQ-5D:
0.41 vs. 0.58; ES -0.6) at baseline than PPS- patients. The higher illness severity
(HAMD17: 7.0 vs. 4.6; ES 0.4) and lower QoL (EQ-5D: 0.83 vs. 0.92; ES -0.6) of PPS
patients persisted after 3 months. CONCLUSIONS: Employed patients reported a
higher QoL and a lower symptomatic burden than unemployed patients. Patients
with a low QoL were more likely to be unemployed. The QoL of Chinese MDD
patients improved over 3 months of naturalistic treatment. The presence of PPS
was associated with higher illness severity and lower QoL at baseline and after 3
months.
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OBJECTIVES: Health-related Quality of Life (HRQoL) has become both a target of
intervention and a crucial outcome in evaluating treatment of alcohol dependence.
Little has been studied on the factors associated with HRQoL before alcohol depen-
dence treatment. We explored the association between HRQoL and several risk
factors including level of alcohol consumption. METHODS: We used data from
CONTROL, an observational cohort study on 143 alcohol dependent patients from
Lausanne hospital, Switzerland, followed for 12 months. Average daily alcohol
consumption was collected every month and categorised according to the World
Health Organisation’s risk levels (WRL) classification: high, medium, low or absti-
nent. Other measures were collected every three months: HRQoL (SF-36), Beck
inventory depression score (BDI) and sociodemographic characteristics. The mean
score for each dimension and for the Physical and Mental Component Summary
Score (PCS and MCS) were calculated at baseline and at 12-months. Correlates of
MCS and PCS were identified using Pearson correlation coefficients and factors
associated with change from baseline to 12-months were identified using linear
mixed models. RESULTS: At baseline, except for physical functioning, all average
SF-36 scores were below those in the general population. The most impaired scores
were those with the heavier contribution to MCS. MCS was significantly correlated
with BDI, WRL and age. Compared to abstinent patients, difference in MCS scores
was significantly lower in patients with medium (difference-12.9; p0.005) or
high risk (difference-14.8; p0.0001) levels whereas no significant difference was
observed between abstinent and low risk patients (difference-7.3; N.S.). Change in
MCS from baseline to 12-months was associated with BDI and WRL. No significant
association was found with PCS. CONCLUSIONS: HRQol is significantly in alcohol-
dependent patients. The level of alcohol consumption and depression appeared as
important drivers of HRQoL related to mental health.
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OBJECTIVES: To describe treatment characteristics among children with Attention
Deficit/Hyperactivity Disorder (ADHD) using atomoxetine in two European
countries. METHODS: Medical charts of patients aged 6-17 with 1 diagnosis of
ADHD between 1/2004-6/2007 were reviewed by physicians from 6 European coun-
tries. All patients had 2 years of follow-up data and received pharmacological or
behavioral therapy post-diagnosis, and were not enrolled in a clinical trial. This
analysis focused on two countries with the largest samples of Strattera® (atomox-
etine HCL) users: UK (UK) and Italy (IT). Outcomes presented include descriptive
statistics (means, rates, percentages) describing treatment: patterns, response and
satisfaction. RESULTS: 94 patients met inclusion criteria (UK [n51], IT [n43]).
Patients were predominantly male 80.4% (UK) and 76.7% (IT), Caucasian, 88.2% and
95.3% and mean (SD) age at diagnosis was 9.5(2.6) and 9.0(2.9). Most patients were
diagnosed via the Connors (76.5%) (UK) or DSM-IV (51.1%; IT) criteria. A majority of
patients presented as combined type ADHD (hyperactive/impulsive and inatten-
tive symptoms) (UK 74% and IT 62%). Between 63% to 76% of all patients indi-
cated 8 impairment for impulsivity and hyperactivity (scale from 0 “no impair-
ment” to 10 “high level impairment”). 76.5% (UK) and 55.8% (IT) of patients received
two or more ADHD treatments and 42.1% and 20.5% received a methylphenidate
product; 37.3% and 32.6% of physicians in the UK and IT, respectively, indicated
that these patients had a “poor” or “very poor” response to methylphenidate. 64.9%
of patients were currently prescribed atomoxetine vs. 35.1% previously prescribed.
23.0% of physicians of current patients indicated that they were “neither satisfied
nor dissatisfied,” “moderately dissatisfied,” or “very dissatisfied” with current ato-
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